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Abstract
Background: Variants in the complement cascade genes and the LOC387715/HTRA1, have been widely reported to associate
with age-related macular degeneration (AMD), the most common cause of visual impairment in industrialized countries.
Methods/Principal Findings: We investigated the association between the LOC387715 A69S and complement component
C3 R102G risk alleles in the Finnish case-control material and found a significant association with both variants (OR 2.98,
p=3.75610
29; non-AMD controls and OR 2.79, p=2.78610
219, blood donor controls and OR 1.83, p=0.008; non-AMD
controls and OR 1.39, p=0.039; blood donor controls), respectively. Previously, we have shown a strong association
between complement factor H (CFH) Y402H and AMD in the Finnish population. A carrier of at least one risk allele in each of
the three susceptibility loci (LOC387715, C3, CFH) had an 18-fold risk of AMD when compared to a non-carrier homozygote
in all three loci. A tentative gene-gene interaction between the two major AMD-associated loci, LOC387715 and CFH, was
found in this study using a multiplicative (logistic regression) model, a synergy index (departure-from-additivity model) and
the mutual information method (MI), suggesting that a common causative pathway may exist for these genes. Smoking
(ever vs. never) exerted an extra risk for AMD, but somewhat surprisingly, only in connection with other factors such as sex
and the C3 genotype. Population attributable risks (PAR) for the CFH, LOC387715 and C3 variants were 58.2%, 51.4% and
5.8%, respectively, the summary PAR for the three variants being 65.4%.
Conclusions/Significance: Evidence for gene-gene interaction between two major AMD associated loci CFH and LOC387715
was obtained using three methods, logistic regression, a synergy index and the mutual information (MI) index.
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Introduction
Age-related macular degeneration (AMD [MIM 603075]) is the
most common cause of irreversible visual loss in the elderly in the
Western world. It is characterized by drusen deposits in its early
forms. The late forms are geographic atrophy and exudative
AMD, which especially affects central vision [1]. AMD is a
complex disease with both genetic susceptibility and environmen-
tal risk factors contributing to the disease pathogenesis. Of the
environmental risk factors, age and smoking have most consis-
tently been identified as major risks [2,3]. In the past few years,
research into the genetics of AMD has been very successful. An
association between the Y402H polymorphism of the complement
factor H (CFH [MIM 134370]) gene on chromosome 1 and AMD
has been confirmed in several Caucasian populations [4–19]. In
addition, an association between the LOC387715/high temperature
requirement factor A-1 (HTRA1) locus on chromosome 10q and AMD
both in Caucasian, and in Japanese and Chinese populations has
been found [11,20–31]. Due to the close proximity of
LOC387715/HTRA1 and controversial results in functional studies
[27,32–34] the true disease-associated variant at this locus has
remained so far unknown.
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complement component 3 (C3 [MIM 120700]) gene of complement
cascade was associated with AMD in two case-control sets [35]
and confirmed in a large case-control sample [36]. With regard to
the previously observed association to CFH this is an interesting
observation because CFH is known to inhibit activation of C3 in
the complement system [37].
We have previously shown that the CFH Y402H polymorphism
is associated with AMD in Finnish patients [16]. Here we
investigated whether the LOC387715 A69S (rs10490924), HTRA1
promoter (rs11200638), or C3 R102G (rs2230199) variants are
associated with AMD in the Finnish population. In addition, we
compared three different statistical methods to estimate the
combined risks and gene-gene and gene-environment interaction
of CFH Y402H, LOC387715 A69S, C3 R102G, and smoking to
the development of AMD.
Materials and Methods
Patient material
The patient material comprised 332 Finnish patients with AMD
attending the Departments of Ophthalmology of Helsinki
(n=201), Oulu (n=10) and Kuopio (n=39) University Hospitals,
or private offices and outpatient clinics (n=82) [16]. A total of 151
patients were sporadic cases with no known relatives with AMD
and 181 were familial cases with at least one first or second degree
relative with AMD. Of the 154 sporadic AMD cases in our
previous study [16] we excluded two patients because of
genotyping failure and one of the sporadic cases was reported to
have a novel AMD case in his family and was thus transferred to
the familial group. Of the 181 previous familial cases one from
Kuopio University Hospital could not be genotyped because of
insufficient sample. Otherwise the patient material was the same as
in our previous study (Table S1). We had two control groups, as
previously reported [16]: 105 age-matched non-AMD controls
with no large drusen and no or minimal focal pigmentary
abnormalities and 350 anonymous blood donor controls.
In the family members of the index patients, the AMD stage was
verified from fundus photographs or angiograms in 45 (60.0%),
from the medical records in 28 (37.3%) and from an examination
by a retinal specialist belonging to the study group in two of the
patients (2.7%). In the rest of the subjects (index cases, sporadic
cases and non-AMD controls) the AMD stage was verified from
fundus photographs or angiograms in 338 (93.4%), from an
examination by a retinal specialist belonging to the study group in
four (1.1%) and from medical records in 20 (5.5%) of the subjects.
The verification of the AMD status of patients was carried out as
described in [16]. Blood samples for genotyping were obtained
from all the patients with AMD and control individuals. We chose
to use two control groups, 105 ophthalmologically investigated
non-AMD controls, and 350 anonymous blood donor controls.
Information on smoking was available in only the non-AMD
controls. The study was approved by the Ethics Committee of the
Helsinki University Eye and Ear Hospital and The Red Cross
Blood Transfusion Service, Helsinki, Finland, and performed in
accordance with the Declaration of Helsinki. Informed consent
was obtained from all of the subjects after explanation of the
nature and possible consequences of the study.
Information on smoking
Information about the smoking history of the study participants
was obtained by telephone. The following data were recorded:
Had a participant ever smoked, the ages at which he/she started
and quit (if he/she had quit) smoking, as well as the numbers of
cigarettes smoked per day during that period. Then, the numbers
of pack-years were calculated (cigarettes smoked per day6years
smoked/20 [cigarettes per pack]). A binary variable, never/ever,
was based on the information obtained on whether a study
participant had smoked ,one pack-year (never-smoker), or .one
pack-year (ever-smoker) in his/her lifetime.
Genotyping
The genotyping procedure for CFH was described in the previous
article [16]. The DNA of the study subjects was amplified by the
polymerase chain reaction (PCR) and sequenced using primers for
LOC387715 rs10490924 forward 5-GGTGGTTCCTGTG-
TCCTTCA-3 and reverse 5-GGGGTAAGGCCTGATCATCT-3
[29], for HTRA1 rs11200638 forward 5-ATGCCACCCACAA-
CAACTTT-3 and reverse 5-CGCGTCCTTCAAACTAATGG-3
[27], and for C3 rs2230199 forward 5-GGAACAGACCCCTGA-
CAATG-3 and reverse 5-CTTGTGGTTGACGGTGAAGA-3.
Amplification was performed in a DNA 2720 Thermal Cycler
(ABI, Foster city, CA, USA). The polymerase chain reaction
conditions were as follows: 5 min at 94uC followed by 35 cycles of
the denaturation step: 30 s at 94uC; the annealing step: 30 s at 59uC
(rs10490924), 52uC (rs 11200638) and 60uC (rs2230199); the
elongation step: 45 s at 72uC; and final extension for 7 min at
72uC terminated the reaction after final annealing. Sequencing was
performed using cycle sequencing with the Big Dye Terminator kit
(version 3.1) supplied by Applied Biosystems (ABI, Foster City, CA,
USA), and reactions were run on an ABI 3730 capillary sequencer
according to the manufacturer’s instructions.
Statistical analysis
Allele and genotype frequencies were estimated by direct
counting. Deviations from Hardy-Weinberg Equilibrium (HWE)
were tested with the standard Chi square test separately in cases
and controls, to identify possible genotyping problems. No
deviations were found (p.0.5 for all tests). The overall success
rate in genotyping was 99.5%. The LOC387715 rs10490924 and
HTRA1 rs11200638 were found to be in almost perfect LD with
each other (D9=0.99).
Individual SNPs
The allelic and genotypic associations of the individual loci
(LOC387715 rs10490924, HTRA1 rs11200638, C3 rs2230199)
were measured by the standard Pearson’s Chi square test with one
degree of freedom (or Fisher’s exact test, where necessary).
Marginal odds ratios (OR) and their confidence intervals were
estimated for all significantly associated loci to assess the strength
of the association. This was carried out with R scripts freely
available on the Internet (R Package Epitools (http://sites.google.
com/site/medepi/epitools, function odds ratio). Furthermore,
population attributable risks (PAR) were estimated with Levin’s
formula; (100%6proportion of exposed6(OR21))/(proportion of
exposed6(OR21)+1)), where the proportion of exposed is the
frequency the allele or genotype in the blood donor controls).
Descriptive analyses of G6G interactions
Joint ORs for pairs of loci (CFH Y402H and LOC387715 A69S;
LOC387715 A69S and C3 rs2230199; CFH Y402H and C3
rs2230199) were calculated for each 2-locus genotype separately,
using the non-risk double homozygote genotype (TTGG, GGCC,
TTCC, respectively) as a reference (Table 1). All patients with
AMD (n=332) were compared to blood donor controls (n=350).
The estimation was carried out with the aforementioned R
package Epitools.
Interactions in AMD
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Multivariable logistic regression was used for assessing the
relationship between the independent variables and the outcome,
estimating the effects of the individual SNPs and covariates (age, sex,
smoking), and for dissecting potential gene-gene (G6G) and gene-
environment (G6E) interactions in our data. This was carried out
with the SPSS Binary logistic regression modeling procedure, in
which stepwise backward variable selection procedure was used to
screen out the informative covariates from the uninformative. We
coded the loci genotypes following the notation presented by Cordell
(2002) and North et al(2005)[38,39],tobeable toassess theadditive
and dominance effects separately, and to compare our numerical
results to those obtained by e.g. Schmidt et al 2006 [21], who used
the same notation. The data was restricted to the patients and non-
AMD controls, since no smoking data was available from the blood
donor controls. A series of models, which included the additive and
dominance effects for each locus (CFH Y402, LOC387715 A69S and
C3 R102G) and environmental effects (sex, smoking) and various
G6G, G6Ea n dE 6E interactions were fitted to the data. The non-
nested models were compared by the means of Akaike’s information
criterion (AIC), where there is a difference of 2 or more between the
AICs of the models including and excluding the term in question,
respectively, is taken as evidence of a significantly better fit to the
data (as suggested by North et al. 2005) [39]. The existence of
dominance effects of individual loci could be ruled out. Thus, at the
next stage, when the possible interactions were examined in more
detail, only the additive genetic terms (and no dominance terms)
were allowed for. This was also necessary in order to keep the
number of parameters in the model to a reasonable number.
In addition to the logistic regression approach, which is known to
have only modest powers for distinguishing interactions [40,41], the
possible interactions were further sought using two complementary
approaches. i) Departure from the additivity model as described by
Rothman [42] and implemented by Andersson et al. 2005 (www.
epinet.se) [43]. Rothman has shown that independent risk factors
adhere to an additive model where interaction is assessed based on
departure from additivity of the disease rates.In this model,biological
interaction(thatisdifferentfromthetermbiologicalinteractionincell
biology) is assessed using three measures: RERI (the relative excess
risk due to interaction), AP (the attributable proportion due to
interaction) and S (the synergy index) [43]. A synergy indexexceeding
1.00 suggests the presence of at least one shared (metabolic) pathway
in the pathogenesis of the disease, where both of the risk factors are
required. ii) the mutual information-based statistics for testing
interaction between two unlinked loci. Mutual information statistics
is designed to measure the dependence between two random
variables that can be detected by testing their independence (Methods
S1) [44]. Logistic regression analyses and synergy index were
calculated either with the SPSS (SPSS Inc., Chicago, Illinois; release
15.0, 2006) statistical software or with R language. We considered
two loci G1 and G2, with each locus having two alleles.
Results
Individual genetic effects
The AMD-associated LOC387715 A69S risk allele T was over-
represented in our patient material with the T allele frequency
reaching 48% in AMD cases compared to 19.5% in non-AMD
controls (p=3.75610
29) and 24.7% in blood donor controls
(p=2.78610
219) (Tables S2, S3 and S4). Both familial and
sporadic cases also carried the LOC387715 risk genotype TT
more often than the GG genotype (compared to the non-AMD
controls: p=2.73610
212 ; familial and p=9.95610
27; sporadic
cases or compared to the blood donor controls : p=1.35610
215 ;
familial and p=8.48610
27; sporadic cases). The difference
between the genotype frequencies in the familial and sporadic
cases (Table S2) was not statistically significant (p=0.09).
We also analyzed the HTRA1 rs 11200638 polymorphism
(Table S2). LOC387715 rs10490924 and HTRA1 rs11200638 are
located only 6.1 kb from each other, and correspondingly, we
observed only 5 genotypes out of 787 that were different among
these two variants. This is inconsistent with perfect LD between
the two SNPs. As there is accumulating evidence for LOC387715
A69S to be the actual causal variant in AMD [32,33], we focused
on the association analyses of the LOC387715 gene in this study.
The C3 R102G variant corresponding to the electrophoretic
protein variant C3F (fast), was associated with AMD in familial
cases when compared to non-AMD controls (p=0.008) or to blood
donor controls (p=0.039) (Tables S2, S3 and S4). The
heterozygous risk genotype CG was also detected more often in
familial cases than in non-AMD or blood donor controls with p-
values of 0.013 and 0.049, respectively. However, the difference in
the frequency of the homozygous risk genotype GG between cases
and controls did not to reach statistical significance since there
were too few GG cases in our material. However the trend is clear:
Table 1. Two-locus odds ratios (OR), 95% confidence intervals (95%CI), and p-values for different genotypic combinations of the
complement factor H Y402H (genotypes CC/CT/TT) and the LOC387715 A69S (genotypes TT/TG/GG) polymorphisms.
Genotypic combination of CFH and LOC387715 OR (95%CI) p-value Number of risk alleles
TTGG 1.00 0
CTGG 2.31 (1.09–5.26) 3.42610
22 1
CCGG 8.83 (4.11–20.61) 3.52610
29 2
TTGT 2.89 (1.20–7.31) 2.41610
22 1
CTGT 8.48 (4.19–18.84) 1.18610
210 2
CCGT 14.41 (6.69–33.85) 1.08610
213 3
TTTT 21.38 (6.26–91.39) 2.08610
27 2
CTTT 17.35 (7.03–46.92) 2.75610
211 3
CCTT 26.57 (9.71–83.25) 1.66610
212 4
Eight genotype combinations are compared to the non-risk genotype combination TTGG. The risk alleles are C (CFH)a n dT (LOC387715). All the patients with AMD
(n=332) are compared to the blood donor controls (n=350). Note the strong correlation between number of risk alleles present in each two-locus genotype and the
estimated odd’s ratios.
doi:10.1371/journal.pone.0003833.t001
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heterozygous cases.
The estimated population attributable risks (PAR) for a carrier
of the risk allele of CFHY402H, LOC387715 A69S and C3 R102G
(using blood donor controls as a reference group) were 58.2%,
51.4%, and 5.8%, respectively. The joint population attributable
risk for the three loci was 65.4%. Since carrying a risk allele in one
locus does not exclude also carrying a risk allele in the other locus
the summary PAR is less than the sum of the three single PARs.
The PAR for smoking was 47.7%, note, however that it had to be
estimated using non-AMD controls as a reference group; thus it
cannot be interpreted as a true population-wise figure. Also, it is
not directly comparable to the gene-wise PAR:s given above due
to different reference group used.
Smoking
Odds ratio for smoking was 3.22 (95% CI 1.81–6.09,
p=4.69610
25, non-AMD controls), and the joint OR for the
three loci and smoking was 74.3 (95 %CI 10.81–2123.6,
p=1.54610
27, non-AMD controls).
Joint OR:s
We also assessed the joint OR:s of complement factor H Y402H
(CFH) polymorphism, previously shown to be associated with
AMD in the Finnish population [16], and LOC387715 A69S
polymorphism. Joint analysis of ORs for the two variants showed
that the risk of AMD was 27-fold (p=1.66610
212, blood donor
controls) if an individual had both homozygous risk genotypes, CC
(CFH) and TT (LOC387715), compared to the non-risk genotype
TTGG, respectively, with all the other joint OR:s ranging from 2 to
21 (Table 1). Three-locus risk-allele carrier (CFH Y402H,
LOC387715 A69S and C3 R102G) joint OR:s are given in
Table 2. The risk of AMD was 18-fold for a carrier of at least one
risk allele per susceptibility loci when compared to a non-carrier of
risk alleles at any loci in blood donor controls (Table 2).
Interaction analyses
In the logistic regression modelling, we found highly significant
(p,0.001) additive gene effects for the LOC387715 and CFH loci,
both having approximately the same effect size (Table 3). Also, for
C3 an additive effect was seen (p=0.007), which was slightly
weaker than the individual effects of CFH and LOC387715, but still
made the overall fit of the three-locus model statistically
significantly better than any two-locus models. No dominance
effect could be demonstrated for either CFH Y402H, LOC387715
A69S, or C3 R102G.
Interestingly, an interaction between CFH and LOC387715 was
suggested (p=0.057), with the estimated effect being only a bit
smaller than the additive effect of C3 locus alone. With the
departure-from-additivity model the attributable proportion due
to interaction of the loci was 70% (95%CI 51–89%) and S, the
synergy index 3.79 (95%CI 1.82–7.89) (Fig 1). Also, mutual
information-based (MI) statistics [44] resulted in a p-value of
1.69610
26 supporting the results obtained with logistic regression
analysis and the departure-from-additivity model (Table S5). No
evidence for G6E interaction was obtained with another major
susceptibility gene LOC387715 and smoking (p=0.14) whereas the
G6E interaction with sex (p=1.04610
26) was shown using MI
statistics. Here the higher number of female patients in our study
material might affect the result.
No evidence for an independent effect of smoking could be
detected in the logistic regression modelling in our data (p=0.795).
Instead, E6Ea n dG 6E interactions were suggested: sex6smoking
(p=0.043) and C36smoking (p=0.086). When combined into a 3-
way interaction C36sex6smoking (p=0.016) the 2-way interaction
C36smoking disappeared. The sex6smoking interaction term
preserved borderline significance (now, p=0.065) (Table 3). Based
on the difference in the AICs of the model including the two 2-way
terms vs. one 3-way interaction term proved the latter to be more
parsimonious(datanot shown).However,synergyindex and mutual
information statistics (Table S5) failed to show evidence for
interaction between neither sex, smoking nor C3. Possible
explanations for this complexity in the logistic regression modelling
showed up in further stratified analyses, where we found out that i)
ever-smoker women had 4.68-fold (95%CI 1.95–14.12,
p=3.60610
24) risk of AMD when compared to never-smoker
women,whereasinmenthe odd’sratiowassmaller(OR=2.57)and
of borderline significance (95%CI 0.99–6.86, p=0.054). Thus, the
effect of smoking was more pronounced in women, which also
explains the significance of the sex6smoking interaction. At the
same time it explains why no independent main effect for smoking
Table 2. Three-locus risks (odds ratios [OR], 95% confidence
intervals [95%CI], and p-values) for combinations of the risk
allele carriers and non-carriers of the complement factor H
(CFH) Y402H, the LOC387715 A69S and the complement
component 3 (C3) R102G polymorphisms.
At least one risk allele present in: OR (95%CI) p-value
None 1.00
CFH (C) 5.45 (2.18–16.83) 1.26610
24
LOC387715 (T) 4.89 (1.73–16.43) 3.72610
23
CFH (C) and LOC387715 (T) 15.55 (6.42–47.22) 1.42610
212
C3 (G) 2.12 (0.52–8.70) 0.296
CFH (C) and C3 (G) 5.57 (2.14–17.72) 2.75610
24
LOC387715 (T)a n dC3 (G) 12.59 (3.63–50.89) 3.62610
25
CFH (C) and LOC387715 (T)a n dC3 (G) 17.91 (7.12–55.88) 1.70610
212
Seven combinations are compared to individuals who carry no risk allele. Risk
alleles are C (CFH), T (LOC387715)a n dG (C3). Patients with AMD (n=332) are
compared to blood donor controls (n=350).
doi:10.1371/journal.pone.0003833.t002
Table 3. Final model parameters from the logistic regression
analyses: the logarithm of odds of being a case rather than a
control is explained by genetic effects and their interactions
and a set of covariates (for details, see text), from which an
automatic stepwise procedure selects the final set of
statistically significant variables and estimates their
magnitudes.
Variable p-value Exp(b) 95% CI for Exp(b)
CFH additive effect 0.000 5.774 3.225–10.339
LOC387715 additive effect 0.000 5.537 3.250–9.434
C3 additive effect 0.003 2.421 1.346–4.355
CFH additive6LOC387715 additive 0.057 1.945 0.980–3.863
Sex6smoking 0.065 1.684 0.967–2.931
C3 additive6sex6smoking 0.016 0.429 0.216–0.852
Constant 0.000 6.078
Exp(b) is the coefficient corresponding to a one unit change in the explanatory
variable. Nagelkerke R Square for the final model was 0.431 (n=382).
doi:10.1371/journal.pone.0003833.t003
Interactions in AMD
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significant risk-conferring effect on the non-risk genotype CC, but
the effect is not that strong (and non-significant) in G-carrying
genotypes (although the trend is the same). In the never-smokers,
the C3 G allele predisposed to AMD as expected, whereas,
interestingly, in ever-smokers the effect of G allele was virtually
indistinguishable. iii) C36sex6smoking: here we saw the highest
OR for ever-smoker women with the non-risk genotype CC
(OR=8.55, [95%CI 2.45–58.46], p=0.0002), and non-significant
effects in G-carrying genotypes (though the trend is the same, that is,
smoking predisposed to AMD in all genotype6sex classes, OR:s
around 2). Overall, both smoking and carriership of the G allele
confers risk for AMD, but the effect could be mediated via a
different pathway.
Discussion
Here we report joint risks of three gene (CFH, LOC387715 and
C3) loci, and smoking in AMD. We found tentative evidence for a
gene-gene interaction between CFH and LOC387715, the two
major susceptibility genes of AMD using three different statistical
approaches. The first evidence for interaction was obtained using
logistic regression; however, because the power of logistic
regression to detect interactions is low [40], it de facto necessitated
the use of other, more sensitive methods. Thus we applied the
departure-from-additivity model that is based on additive disease
rates [42,43]. This method has also been used by Despriet et al
[45] who reported increased risks of AMD in CFH risk genotype
carriers with high C-reactive protein serum levels, elevated
sedimentation rate (ESR), leucocyte count and smoking and more
recently by Baird et al., [46] who demonstrated a G6E–
interaction between a pathogenic load of C. pneumoniae and
the CFH Y402H in the aetiology of AMD. The third method,
mutual information statistics, has not been previously utilized in
analyzing risk factors for AMD also suggested strong evidence for
interaction of CFH and LOC387715.
The strong association of the LOC387715 A69S with AMD in
our Finnish patient material is in agreement with previous results
from other populations [11,15,21–24,32,47–51] (Table 4). Fur-
thermore, joint risks for CFH Y402H and LOC387715 A69S were
also of similar magnitude as observed by Rivera et al., [11]. In
addition, the joint additive effect of CFH and LOC387715 has been
shown to be strengthened by rare C2 variants [51]. However,
discoveries of interactions between these loci (or smoking) have
been scarce and they have not been replicated. Thus, we want to
point out that most of the analyses of G6G and G6E interaction
have been based on logistic regression modelling [11,15,21,22,47],
which according to our present state of understanding is
statistically not a very powerful approach [40,41]. Thus, re-
analysis of existing data with more sensitive methods for detecting
interaction might, possibly, change the picture a bit. Indeed, a true
biological interaction between CFH and LOC387715 would be
plausible based on recent cell biological data by Kanda et al.
(2007) and Fritsche et al. (2008) showing that LOC387715 is
localized to mitochondria [32,33] and on the earlier evidence that
mitochondria activate complement [52]. Interestingly, mitochon-
drial dysfunction involving altered mitochondrial translation,
import of nuclear-encoded proteins, and ATP-synthase activity
was suggested in recent proteomics studies on retinal pigment
epithelium (RPE) in AMD by age [53]. Further cell and
neurobiological studies are warranted to elucidate whether the
CFH and the LOC387715 genes indeed belong to a common
causative pathway.
AG 6E interaction between CFH Y402H and smoking could be
detected in our material using MI statistics (p=8.24610
24; Table
S5). In the Rotterdam study increased risks of AMD in CFH risk
genotype carriers with smoking, elevated C-reactive protein serum
levels, sedimentation rate (ESR) and leucocyte count were
Figure 1. Measures of biological interactions between LOC387715 A69S (LOC) and CFH Y402H (CFH). Regression coefficients for the
calculations of the estimates were obtained from a separate logistic regression model as described by Andersson et al., 2005 [43] www.epinet.se.
Figures in parenthesis after measures indicates values with no interaction.
doi:10.1371/journal.pone.0003833.g001
Interactions in AMD
PLoS ONE | www.plosone.org 5 December 2008 | Volume 3 | Issue 12 | e3833reported using the departure from additivity model (synergy index
of 2.38 [95%CI 1.06–5.35]) [45] concordant with our results. An
interaction between smoking and CFH would be plausible, since
cigarette smoke has been shown to activate the complement
system [54]. Smoking also increases serum CRP concentrations
[55] and further, impaired binding of C-reactive protein to the CC
or CT variants of CFH (Y402H) has been detected [56,57].
However, in studies using logistic regression analyses smoking and
CFH Y402H have consistently been found to be statistically
independent risk factors for AMD [15,58–60].
We did not find an interaction between LOC387715 and
smoking with any of the three statistical methods used that is in
agreement with several previous findings [15,23,48,60], although
Schmidt et al. have reported a statistical interaction between
LOC387715 and smoking [21] and most recently, an interaction
between HTRA1 rs11200638 and smoking was reported [34].
Here we also demonstrate that C3 seems to have a milder,
though a statistically significant effect on AMD, as noted earlier
[35,36] (Table 5). Accordingly, the risk of AMD was 16-fold for a
carrier of at least one risk allele at both CFH Y402H and
LOC387715 A69S loci, while adding the risk allele of the C3
R102G increased the OR to only 18 using logistic regression
analysis (Table 2). C3 plays a crucial role in all the three pathways
of the complement system, the classic, the lectin and the
alternative pathway [37]. C3 has also been identified in drusen
deposits, the hallmarks of AMD [7]. Considering this, the G6G
interaction of C3 and CFH Y402H in AMD obtained using MI
statistics is reasonable. Furthermore, activation of an alternative
pathway of the complement system by cigarette smoke has been
shown to be mediated by C3 [61,62]. Considering this it would be
reasonable to think that a true C36smoking interaction might
have exist.
The population attributable risks (PAR) for the CFH Y402H
(58.2%) and LOC387715 A69S (51.4%) are in line with other
reports where PARs for CFH Y402H range from 43 to 68 %
[5,13,15,20,21] and for LOC387715 A69S from 36 to 57%
[15,20,21]. Instead, the PAR for C3 R102G in Yates et al. was
higher (22%) [35] than what we obtained (5.8%). It is possible that
the C3 G allele effect is diluted in our data by the stronger effect of
CC genotype in ever-smoking women (C36sex6smoking). Schmidt
Table 4. Table summarizes odds ratios (OR) and 95% confidence intervals (CI) of our current study and previous studies on the
LOC387715 A69S polymorphism.
Study AMD cases (n) Controls (n) ORhet (95% CI) ORhom (95%CI)
This study 332 105 3.37 (2.09–5.52) cases compared
to 105 non-AMD controls
17.69 (6.23–76.92)
350 2.77 (1.98–3.89) cases compared
to 350 blood donor controls
7.39 (4.42–12.77)
Rivera et al. 2005 1120 922 2.69 (2.22–3.27) 8.21 (5.79–11.65)
Schmidt et al. 2006 610 259 1.65 (1.12–2.43) 5.73 (3.07–10.71)
Conley et al. 2006 AREDS sample 701 175 3.06 (2.13–4.39) 17.26 (6.22–47.89)
CHS sample 126 1051 1.58 (1.05–2.39) 4.75 (2.56–8.80)
Tanimoto et al. 2007 95 99 2.15 (1.16–4.03)*
Ross et al. 2007 NEI sample+ AREDS sample 399 329 2.61 (1.89–3.61) 8.59 (4.49–16.46)
BMES sample 278 557 1.69 (1.25–2.28) 2.20 (1.05–4.62)
Kanda et al. 2007 535 288 2.66{ 7.05{
ORhet refers to comparison of GT to GG and ORhom to comparison of TT to GG. T allele is the risk allele.
AREDS Age-Related Eye Disease Study
CHS Cardiovascular Health Study
*OR for individuals having one or both risk alleles (T)
NEI National Eye Institute
BMES Blue Mountains Eye Study
{relative risk
doi:10.1371/journal.pone.0003833.t004
Table 5. Table summarizes odds ratios (OR) and 95% confidence intervals (CI) of our current study and previous studies on the
complement component 3 (C3) R102G polymorphism.
Study AMD cases (n) Controls (n) ORhet (95% CI) ORhom (95%CI)
This study 332 105 1.64 (1.00–2.75) cases compared
to 105 non-AMD controls
1.92 (0.61–8.82)
350 1.21 (0.87–1.67) cases compared
to 350 blood donor controls
1.30 (0.62–2.79)
Yates et al. 2007 English group 603 350 1.6 (1.2–2.2) 2.4 (1.3–4.4)
Scottish group 505 351 1.8 (1.2–2.6) 2.9 (1.4–5.9)
Maller et al. 2007 1238 934 1.61 3.26
ORhet refers to comparison of CG to CC and ORhom to comparison of GG to CC. C allele is the risk allele.
doi:10.1371/journal.pone.0003833.t005
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thus lower than ours (47.7%), but here it should be noted that we
could not estimate the true population-based PAR due to a lack of
smoking information in our blood donor controls, and hence ours
may be an overestimate. However, the ever-smokers’ risk is
mediated through the non-risk genotype CC of the C3 gene
whereas in the never-smokers the risk effect comes from the
reported risk allele warrants further studies.
In conclusion, analysis of gene-gene and gene-environment
interaction of risk factors in AMD benefits from combination of
several statistical methods and the available biochemical data.
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